These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 28615036)

  • 21. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
    Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
    J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
    van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
    Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
    Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
    J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease.
    Shih YJ; Yang YH; Lin CY; Chang CL; Chiang BL
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):58. PubMed ID: 31443722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
    Donnithorne KJ; Cron RQ; Beukelman T
    J Rheumatol; 2011 Dec; 38(12):2675-81. PubMed ID: 22089470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
    Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
    PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
    Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
    J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.
    Arnstad ED; Rypdal V; Peltoniemi S; Herlin T; Berntson L; Fasth A; Nielsen S; Glerup M; Ekelund M; Zak M; Aalto K; Nordal E; Romundstad PR; Rygg M;
    Arthritis Care Res (Hoboken); 2019 Jul; 71(7):961-969. PubMed ID: 30055093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
    Windschall D; Müller T; Becker I; Horneff G
    Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.
    Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Gulli R; Mandich P; Puppo F
    Mod Rheumatol; 2018 May; 28(3):417-431. PubMed ID: 28837372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
    Su Y; Yang YH; Chiang BL
    Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Windschall D; Müller T; Becker I; Horneff G
    Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.